Top FDA officials were aware of the surveillance and monitoring programs targeting agency employees who raised questions about certain medial device review practices, according to a letter obtained by the Wall Street Journal.
Agency leadership, including Commissioner Dr. Margaret Hamburg and medical devices chief Dr. Jeffrey Shuren, were apprised of surveillance efforts against a group of medical device reviewers accused of leaking proprietary information to the media, according to the letter.